Abstract

BackgroundScientific evidence supports decision-making on the use of implantable medical devices (IMDs) in clinical practice, but IMDs are thought to be far less investigated than drugs. In the USA, studies have shown that approval process of high-risk medical devices was often based on insufficiently robust studies, suggesting that evidence prior to marketing may not be adequate. This study aimed to ascertain level of evidence available for IMDs access to reimbursement in France.MethodsThe objective was to examine the scientific evidence used for IMDs assessment by the French National Authority for Health. We collected all public documents summarising supportive clinical data and opinions concerning IMDs issued in 2008. An opinion qualifies the expected benefit (EB) of the IMD assessed as sufficient or insufficient, and if sufficient, the level of improvement of the expected benefit (IEB) on a scale from major (level I) to no improvement (level V). For each opinion, the study with the highest level of evidence of efficacy data, and its design were collected, or, where no studies were available, any other data sources used to establish the opinion.ResultsOne hundred and two opinions were analysed, with 72 reporting at least one study used for assessment (70.6%). When considering the study with the highest level of evidence: 34 were clinical non-comparative studies (47.2%); 29 were clinical comparative studies of which 25 randomised controlled trials (40.3%); 5 were meta-analyses of randomised controlled trials (6.9%); and 4 were systematic literature reviews (5.6%). The opinions were significantly different according to the study design (p < 0.001). The most frequent design for insufficient EB, IEB level V and IEB level IV was a non-comparative study (10/19, 52.6%; 15/24, 62.5%; and 8/15, 53.3%; respectively). For the 30 opinions with no supporting clinical study, 16 (53.3%) were based on an expert-based process, 9 (30.0%) were based on the conclusions of a previous opinion (all concluding IEB level V), and 5 (16.7%) reported no data (concluding insufficient EB for 4 and IEB level V for 1).ConclusionsThis study confirmed that level of evidence of clinical evaluation of IMDs is low and needs to be improved.

Highlights

  • Scientific evidence supports decision-making on the use of implantable medical devices (IMDs) in clinical practice, but IMDs are thought to be far less investigated than drugs

  • Opinions An opinion is the result of CNEDIMTS assessment of safety and efficacy of a device in a specified indication, expressed by the qualification of its “expected benefit” (EB) as insufficient or sufficient; in the latter case its “improvement of expected benefit” (IEB) level is documented

  • improvement of the expected benefit (IEB) is given in comparison to the established standard of care: level I means there is a major improvement in expected benefit with the IMD; level II is a significant improvement; level III is a moderate improvement; level IV is a minor improvement; and level V is no improvement

Read more

Summary

Introduction

Scientific evidence supports decision-making on the use of implantable medical devices (IMDs) in clinical practice, but IMDs are thought to be far less investigated than drugs. In France, the government set up the French National Authority for Health (Haute Autorité de Santé, HAS) in August 2004, whose activities are designed to improve the quality of patient care and guarantee equity within the healthcare system These activities include the assessment of medical devices based on scientific expertise, carried out by a dedicated committee (Commission Nationale d’Evaluation des Dispositifs Médicaux et Technologies de Santé, CNEDIMTS) [7]. The aim of these assessments is to provide “opinions” to health authorities that contain the information needed to support decisions regarding the reimbursement. All assessed medical devices qualified with “sufficient expected clinical benefit” are included on the list of products and services qualifying for reimbursement [8]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call